POSSIBILITY OF BONE METABOLISM MODULATOR (STRONTIUM RANELATE) USAGE FOR THE TREATMENT OF WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS AND ARTERIAL HYPERTENSION
https://doi.org/10.20996/1819-6446-2009-5-2-18-21
Abstract
Aim. To study effect of the bone metabolism modulator strontium ranelate on bone mineral density (BMD) and to evaluate it pleiotropic effects on cardiovascular remodeling in women with postmenopausal osteoporosis (PO) and a arterial hypertension (HT).
Material and methods. 45 women with PO, HT (1-2 stage) and medium/high cardiovascular risk were included in the study. 23 patients of the main group received strontium ranelate 2 g once daily additionally to antihypertensive and calcium replacement therapies. Before therapy and after 10 months MBD was evaluated by dual-energy x-ray absorbtiometry (DEXA) with usage of peripheral densitometer. Strontium ranelate effects on carotid intima-media thickness (duplex scanning) and morphofunctional cardiac indices (echocardiography) also were assessed.
Results. Strontium ranelate therapy in patients with PO and HT leads to BMD rising and retardation of cardiovascular remodeling.
Conclusion. Strontium ranelate is effective antiosteoporotic drug with positive influence on morphofunctional cardiac indices and carotid intima-media thickness.
About the Authors
N. J. Hozjainova
Smolensk State Medical Academy of Roszdrav
Russian Federation
Russian Federation
ul. Krupskoy 28, Smolensk, 214019 Russia
V. M. Tsareva
Smolensk State Medical Academy of Roszdrav
Russian Federation
Russian Federation
ul. Krupskoy 28, Smolensk, 214019 Russia
T. V. Brook
Smolensk State Medical Academy of Roszdrav
Russian Federation
Russian Federation
ul. Krupskoy 28, Smolensk, 214019 Russia
M. S. Bezaltynnyh
Smolensk State Medical Academy of Roszdrav
Russian Federation
Russian Federation
ul. Krupskoy 28, Smolensk, 214019 Russia
References
1. Маличенко С.Б., Колосова И.Р., Варежкина И.А. Первичный остеопороз: взаимосвязь патологии костной и сердечно-сосудистой системы у пожилых. Consilium Medicum 2004;6(12):1032-43.
2. Маличенко С.Б. Постменопаузальный симптомокомплекс: роль кальция и витамина D в развитии, профилактике и лечении клинических проявлений эстрогенного дефицита. Consilium Medicum 2005;7(8):1464-75.
3. Насонов Е.Л. Остеопороз и заболевания сердечно-сосудистой системы. Кардиология 2002;(3):80-2.
4. Safar M.E., Smulyan H. Hypertension in women. Am J Hypertens 2004;17(1):82-7.
5. Беневоленская Л.И., редактор. Руководство по остеопорозу. М.: БИНОМ; 2003.
6. Simonet W.S., Lacey D.L., Dunstan C.R. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89(2):309–19.
7. Schoppet M., Preissner K.T., Hofbauer L.C. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22(4):549–53.
8. Bucay N., Sarosi I., Dunstan C.R. et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12(9):1260–8.
9. Min H., Morony S., Sarosi I. et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000;192(4):463–74.
10. Kiechl S., Schett G., Wenning G. et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004;109(18):2175–80.
11. Yano K., Tsuda E., Washida N. et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999;14(4):518–27.
12. Roux C., Reginster J.Y., Fechtenbaum J. et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 2006;21(4):536-42.
13. Brennan T., Rybchyn M.S., Conigrave A.D. et al. Strontium ranelate effect on proliferation and OPG expression in osteoblasts [abstract]. Calcif Tissue Int 2006;78(Suppl 1):S129.
14. Reginster J., Seeman E., De Vernejoul M. eEt al Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocrinol Metab 2005;90(5):2816-22.
15. Kannis J.A., Burlet N., Cooper C. et al. European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19(4):399-428.
Review
For citations:
Hozjainova N.J., Tsareva V.M., Brook T.V., Bezaltynnyh M.S. POSSIBILITY OF BONE METABOLISM MODULATOR (STRONTIUM RANELATE) USAGE FOR THE TREATMENT OF WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS AND ARTERIAL HYPERTENSION. Rational Pharmacotherapy in Cardiology. 2009;5(2):18-21. (In Russ.) https://doi.org/10.20996/1819-6446-2009-5-2-18-21
Views:
596
Email this article 